Veracyte Inc (VCYT) Stock Price, Quote & News

Company Profile

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services. The company...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 650 243 6300

Fax: 650 243 6388

Website: www.veracyte.com

Address:

6000 Shoreline Court, Suite 300, South San Francisco, United States

PhishTourFunds Aug. 19 at 1:26 AM

$VCYT I dream about setups like that…

0 · Reply

ManosDeDiamante07 Aug. 18 at 2:57 PM

$VCYT Killing the game 😎💰

0 · Reply

DonZulu Aug. 14 at 4:28 AM

$VCYT oh shit how did i miss this last week

1 · Reply

PhishTourFunds Aug. 13 at 8:37 PM

$VCYT That was the only order that filled unfortunately…stock now sitting over $30 🔥

1 · Reply

SilverEagle Aug. 13 at 7:52 PM

$VCYT bulls turn.

1 · Reply

PhishTourFunds Aug. 13 at 6:22 PM

$VCYT $30 💪

0 · Reply

PhishTourFunds Aug. 12 at 1:22 PM

$VCYT 22% and climbing 💪

0 · Reply

ZacksResearch Aug. 12 at 12:51 PM

$VCYT surges 15.5% post-earnings — what's driving the momentum? 🚀 Adjusted EPS jumped 46.7% from the year-ago period, smashing estimates by 41.9%, with revenues up 13.8% year over year — thanks to strong Decipher and Afirma test growth 📈. Discover the full earnings breakdown here 👉 https://www.zacks.com/stock/news/2701823/vcyt-stock-gains-on-q2-earnings-and-revenue-beat-margins-up?cid=sm-stocktwits-2-2701823-body-7292&ADID=SYND_STOCKTWITS_TWEET_2_2701823_BODY_7292

0 · Reply

ZacksResearch Aug. 12 at 11:51 AM

$VCYT pops 15% after crushing Q2 🚀 Earnings and revenue topped estimates, with Decipher and Afirma driving growth — margins are expanding too. Full breakdown of the bullish setup here 👉 https://www.zacks.com/stock/news/2701823/vcyt-stock-gains-on-q2-earnings-and-revenue-beat-margins-up?cid=sm-stocktwits-2-2701823-teaser-7291&ADID=SYND_STOCKTWITS_TWEET_2_2701823_TEASER_7291

0 · Reply

GSTX7 Aug. 11 at 8:27 PM

$VCYT Took profit here from the lows. LOTS of potential for longs here. Think they might push it back from the $28 resistance. Will add if it does. Will cry if I'm wrong ... lol

0 · Reply

Veracyte, Inc. (VCYT) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 4:05 PM EDT - 16 days ago

Veracyte Announces Second Quarter 2025 Financial Results

Jul 17, 2025, 5:30 PM EDT - 5 weeks ago

Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025

Jul 8, 2025, 4:05 PM EDT - 6 weeks ago

Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025

May 28, 2025, 4:05 PM EDT - 3 months ago

Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research

May 20, 2025, 5:00 PM EDT - 3 months ago

Veracyte to Participate in Upcoming Investor Conferences

May 8, 2025, 12:49 AM EDT - 3 months ago

Veracyte, Inc. (VCYT) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 3 months ago

Veracyte Announces First Quarter 2025 Financial Results

Apr 25, 2025, 7:00 AM EDT - 4 months ago

Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer

Apr 22, 2025, 9:00 AM EDT - 4 months ago

Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting

Apr 21, 2025, 4:05 PM EDT - 4 months ago

Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database Release

Mar 25, 2025, 4:05 PM EDT - 5 months ago

New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

Mar 19, 2025, 5:00 PM EDT - 5 months ago

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

Feb 25, 2025, 10:32 AM EST - 6 months ago

Solid Growth, Soft Outlook: Why I'm Holding On Veracyte

Feb 25, 2025, 10:16 AM EST - 6 months ago

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive

Feb 24, 2025, 10:53 PM EST - 6 months ago

Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 4:05 PM EST - 6 months ago

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 14, 2025, 8:30 AM EST - 6 months ago

New Data at ASCO GU Show Power of Veracyte's Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

Feb 11, 2025, 8:30 AM EST - 6 months ago

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests' Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

Feb 5, 2025, 8:30 AM EST - 7 months ago

New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

Feb 4, 2025, 4:30 PM EST - 7 months ago

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

Dec 5, 2024, 4:05 PM EST - 9 months ago

Veracyte's Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

Nov 6, 2024, 10:49 PM EST - 10 months ago

Veracyte, Inc. (VCYT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 10 months ago

Veracyte Announces Third Quarter 2024 Financial Results

Oct 16, 2024, 6:43 PM EDT - 11 months ago

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

Sep 15, 2024, 8:45 AM EDT - 1 year ago

New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer

Sep 4, 2024, 4:05 PM EDT - 1 year ago

Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors

Aug 26, 2024, 5:30 PM EDT - 1 year ago

Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 26, 2024, 9:00 AM EDT - 1 year ago

Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle

Aug 7, 2024, 2:08 PM EDT - 1 year ago

Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View

Aug 6, 2024, 10:17 PM EDT - 1 year ago

Veracyte, Inc. (VCYT) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Second Quarter 2024 Financial Results

Jul 17, 2024, 5:00 PM EDT - 1 year ago

Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024

Jun 3, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors

May 22, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer

May 7, 2024, 4:05 PM EDT - 1 year ago

Veracyte Announces First Quarter 2024 Financial Results

May 6, 2024, 4:05 PM EDT - 1 year ago

14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Apr 22, 2024, 5:00 PM EDT - 1 year ago

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

Apr 22, 2024, 8:30 AM EDT - 1 year ago

New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Apr 16, 2024, 8:30 AM EDT - 1 year ago

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

Feb 27, 2024, 5:55 PM EST - 1 year ago

Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Feb 22, 2024, 9:24 PM EST - 1 year ago

Veracyte, Inc. (VCYT) Q4 2023 Earnings Call Transcript

Feb 22, 2024, 4:05 PM EST - 1 year ago

Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results

Feb 21, 2024, 5:00 PM EST - 1 year ago

Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference

Feb 8, 2024, 8:00 AM EST - 1 year ago

Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Feb 6, 2024, 8:15 AM EST - 1 year ago

Veracyte Completes Acquisition of C2i Genomics

Jan 8, 2024, 8:00 AM EST - 1 year ago

Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform

Dec 12, 2023, 4:30 PM EST - 1 year ago

Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 4:05 PM EST - 1 year ago

Real-World Data Presented at SUO 2023 Show that Veracyte's Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress

Nov 29, 2023, 8:30 AM EST - 1 year ago

Clinical Validation Data Published in CHEST Demonstrate that Veracyte's Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

PhishTourFunds Aug. 19 at 1:26 AM

$VCYT I dream about setups like that…

0 · Reply

ManosDeDiamante07 Aug. 18 at 2:57 PM

$VCYT Killing the game 😎💰

0 · Reply

DonZulu Aug. 14 at 4:28 AM

$VCYT oh shit how did i miss this last week

1 · Reply

PhishTourFunds Aug. 13 at 8:37 PM

$VCYT That was the only order that filled unfortunately…stock now sitting over $30 🔥

1 · Reply

SilverEagle Aug. 13 at 7:52 PM

$VCYT bulls turn.

1 · Reply

PhishTourFunds Aug. 13 at 6:22 PM

$VCYT $30 💪

0 · Reply

PhishTourFunds Aug. 12 at 1:22 PM

$VCYT 22% and climbing 💪

0 · Reply

ZacksResearch Aug. 12 at 12:51 PM

0 · Reply

ZacksResearch Aug. 12 at 11:51 AM

0 · Reply

GSTX7 Aug. 11 at 8:27 PM

$VCYT Took profit here from the lows. LOTS of potential for longs here. Think they might push it back from the $28 resistance. Will add if it does. Will cry if I'm wrong ... lol

0 · Reply

ManosDeDiamante07 Aug. 10 at 10:17 PM

$VCYT

0 · Reply

DanaBlack Aug. 8 at 8:08 PM

$VCYT sorry guys. Started a position here too that’s why it took a massive dump. I’m the stock killer.

0 · Reply

StockArbitrage Aug. 8 at 3:32 PM

$IXHL $VCYT want something less volatile? My call out @25. Showing momentum.

0 · Reply

DanaBlack Aug. 8 at 2:06 PM

$BULL moving profits to $VCYT

0 · Reply

pmb0928 Aug. 8 at 1:54 PM

$VCYT This is a solid investment, institutions all over it. $30-32 by end of next week.

0 · Reply

StockArbitrage Aug. 7 at 6:37 PM

$VCYT Found another customer. https://finance.yahoo.com/news/helix-veracyte-partner-expand-access-130000554.html

0 · Reply

pmb0928 Aug. 7 at 2:54 PM

$VCYT This is such a solid company with continued growth and increased revenue. Institutions are all over it. Cathie Wood is all over it.

0 · Reply

PhishTourFunds Aug. 7 at 11:23 AM

$VCYT 💪

0 · Reply

StockArbitrage Aug. 6 at 9:57 PM

$IXHL Followers, Check out $VCYT huge earnings just released. Blackrock days ago doubled their shares to about 12 Million. Keep Watch on upside potential. Established Cancer AI genomic classifier company. I took shares at $25.

0 · Reply

GSTX7 Aug. 6 at 8:57 PM

$VCYT Big guidance raise across the board!!

0 · Reply

pmb0928 Aug. 6 at 8:55 PM

$VCYT very good earnings. Crushed estimates in EPS and revenue. Back to $30+ soon

0 · Reply

Momabeat Aug. 6 at 8:50 PM

$VCYT thank you Cathie!!!

0 · Reply

Market Cap	2.32B
Revenue (ttm)	445.76M
Net Income (ttm)	24.14M
EPS (ttm)	N/A
PE Ratio	32.05
Forward PE	34.19
Profit Margin	5.42%
Debt to Equity Ratio	0.00

Volume	1,047,700
Avg Vol	1,565,326
Day's Range	N/A - N/A
Shares Out	78.67M
Stochastic %K	91%
Beta	1.97
Analysts	Strong Sell
Price Target	$40.22